"10.1371_journal.pone.0140022","plos one","2015-10-13T00:00:00Z","Maâ€™en Obeidat; Nick Fishbane; Yunlong Nie; Virginia Chen; Zsuzsanna Hollander; Scott J Tebbutt; Yohan BossÃ©; Raymond T Ng; Bruce E Miller; Bruce McManus; Stephen Rennard; Peter D ParÃ©; Don D Sin","The University of British Columbia Centre for Heart Lung Innovation, St Paulâ€™s Hospital, Vancouver, BC, Canada; Prevention of Organ Failure (PROOF) Centre of Excellence, Vancouver, BC, Canada; Respiratory Division, Department of Medicine, University of British Columbia, Vancouver, BC, Canada; Institut universitaire de cardiologie et de pneumologie de QuÃ©bec, Department of Molecular Medicine, Laval University, QuÃ©bec, Canada; Respiratory Therapy Area Unit, GlaxoSmithKline R&D, King of Prussia, Pennsylvania, United States of America; Division of Pulmonary and Critical Care Medicine, University of Nebraska Medical Center, Omaha, Nebraska, United States of America","Conceived and designed the experiments: MO PDP DDS. Performed the experiments: MO NF YN VC PDP DDS. Analyzed the data: MO NF YN VC. Contributed reagents/materials/analysis tools: ZH SJT YB RTN BEM BM SR. Wrote the paper: MO NF PDP DDS.","BEM is an employee and shareholder of GSK. SR has served as a consultant, participated in advisory boards, received honorarium for speaking or grant support from: American Board of Internal Medicine, Advantage Healthcare, Almirall, American Thoracic Society, AstraZeneca, Baxter, Boehringer Ingelheim, Chiesi, ClearView Healthcare, Cleveland Clinic, Complete Medical Group, CSL, Dailchi Sankyo, Decision Resources, Forest, Gerson Lehman, Grifols, GroupH, Guidepoint Global, Haymarket, Huron Consulting, Inthought, Johnson and Johnson, Methodist Health System â€ Dallas, NCI Consulting, Novartis, Pearl, Penn Technology, Pfizer, PlanningShop, PSL FirstWord, Qwessential, Takeda, Theron and WebMD. Since August 10, 2015 he as served as chief clinical scientist, new clinical development, AstraZeneca, UK. DDS: Over the past 3 years, DDS has served as a consultant on AstraZeneca (AZ) and Novartis Advisory Boards for COPD. He has been a consultant with Amgen and Almirall. He has received research funding from AZ and Boehringer Ingelheim (BI). He has given lectures sponsored by BI and AZ. This does not alter the authorsâ€™ adherence to PLOS ONE policies on sharing data and materials.","2015","10","Maâ€™en Obeidat","MO",13,TRUE,3,6,4,4,TRUE,TRUE,FALSE,0,NA,FALSE
